18F-DTBZ ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	6

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02059733 (ClinicalTrials.gov)	February 2013	7/2/2014	Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism	Developing a Novel Imaging Biomarker in the Differential Diagnosis of Parkinson's Disease and Parkinsonism by 18F-DTBZ PET	Parkinson's Disease	Drug: 18F-DTBZ	Chang Gung Memorial Hospital	NULL	Completed	20 Years	80 Years	All	72	Phase 2	Taiwan
2	NCT02039024 (ClinicalTrials.gov)	March 2012	15/1/2014	Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET	Imaging Non-motor Symptoms of Parkinson's Disease by Novel 18F-DTBZ and Florbetapir F-18 PET	Parkinson's Disease	Drug: 18F- DTBZ	Chang Gung Memorial Hospital	National Science Council, Taiwan	Completed	20 Years	80 Years	Both	18	Phase 2	Taiwan
3	NCT01556100 (ClinicalTrials.gov)	November 2011	6/3/2012	Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression	Long-Term Vesicular Monoamine Transporter II Imaging and Clinical Assessment of Parkinson's Disease Progression	Parkinson Disease	Drug: 18F-DTBZ AV-133	Chang Gung Memorial Hospital	NULL	Completed	20 Years	N/A	All	40	Phase 2	NULL
4	NCT01759888 (ClinicalTrials.gov)	August 2011	1/1/2013	Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism	From Mouse Models to Patients: Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism	Parkinson's Disease	Drug: 18F-DTBZ	Chang Gung Memorial Hospital	National Science Council, Taiwan	Completed	20 Years	80 Years	Both	49	Phase 2	Taiwan
5	NCT01824056 (ClinicalTrials.gov)	August 2010	12/3/2013	The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography	The Differential Diagnosis of Parkinson's Disease and Parkinsonism by Positron-emission Tomography With Vesicular Monoamine Transporter Ligand (18F-DTBZ)	Parkinson's Disease	Drug: 18F-FDG	Chang Gung Memorial Hospital	National Science Council, Taiwan	Completed	20 Years	80 Years	Both	120	Phase 2	Taiwan
6	NCT01283347 (ClinicalTrials.gov)	May 2010	11/1/2011	18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging	Phase II Study of 18F-DTBZ: The Differential Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging	Parkinson's Disease	Drug: 18F-DTBZ	Chang Gung Memorial Hospital	NULL	Completed	50 Years	80 Years	Both	100	Phase 2	Taiwan

Back to top